Collaborative Staging for Colon

Slides:



Advertisements
Similar presentations
Geraldine O’Dowd Consultant Pathologist NHS Lanarkshire 18 th November 2014 Colorectal Cancer Pathology: Impact of new guidelines for the laboratory.
Advertisements

STAGING MCR Staff Show Me Healthy Women March 27, 2008 Supported by a Cooperative Agreement between DHSS and the Centers for Disease Control and Prevention.
Esophagus, Esophagus GE Junction, Stomach
AJCC Staging Moments AJCC TNM Staging 7th Edition Rectal Case #3 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
The Anatomy of Collaborative Staging: Ovary Presentation developed by Collaborative Staging Steering Committee 2005 Update.
Cancer Registry Coding Changes for 2014 Presented by the Kentucky Cancer Registry February, 2014.
Coding Pitfalls Jessica K. Dohler, BS, CTR. Objectives 0 Know how to code the Tumor/Ext Eval code when using intraoperative findings 0 Know when to code.
Hematopoietic and Lymphoid Neoplasm Project. Primary Site and Histology Rules Peggy Adamo, RHIT, CTR NCI SEER October 2009.
Credit line: Breast. In: Greene, F.L., Compton, C.C., Fritz, A.G., et al., editors. AJCC Cancer Staging Atlas. New York: Springer, 2006: ©American.
TRAM Educational Conference September 19, 2014 Meritus Medical Center 1.
Directly Coded Summary Stage
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
AJCC TNM Staging 7th Edition Breast Case #3
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #2 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
AJCC Staging Moments AJCC TNM Staging 7th Edition Colon Case #2 Contributors: J. Milburn Jessup, MD Cancer Diagnosis Program, DCTD, NCI, Rockville, Maryland.
Coding Factoids and Frequently Asked Questions Education & Training Team Collaborative Stage Data Collection System Version 1 (CSv2)
Eleni Galani Medical Oncologist
Colon Cancer First Page.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
1 MP/H Coding Rules General Instructions MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
Slides last updated: March 2015 CRC: STAGING. How colorectal cancer (CRC) is staged 1 Stage describes the extent of cancer, and is one of the most important.
Cancer Staging.
Putting the Puzzle Together: Breast Collaborative Staging Melissa Riddle, RHIT, CTR October 6, 2012.
CSv2 101 Education & Training Team Collaborative Stage Data Collection System Lecture Version 1.0.
EVALUATION OF LYMPH NODES & PATHOLOGIC EXAMINATION FOR BREAST CASES Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry.
Head and Neck Schematic diagram indicating the location of the lymph node levels in the neck as described in Tables II.1 and II.2. Compton, C.C., Byrd,
1 Myeloma Plasma Cell Disorders (Schema Name: MyelomaPlasmaCellDisorder) V0203.
AJCC 6 TH EDITION STAGING OF BREAST CARCINOMA. AJCC NODE STAGING -16 CATEGORIES pNX – 1 option pN0 – 5 options; null,(i-),(i+),(mol-),(mol+) pN1 – 4.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
VS. CSv2 Changes CSv2 compared to CSv1 Part 1, Section 1.
Anatomic sites and subsites of the vulva.
Liver Anatomy of the liver with division into right and left lobes by the plane of Rex-Cantlie line. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging.
Gallbladder Schematic of the gallbladder in relation to the liver and biliary tract. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas,
Urinary Bladder Anatomical sites of the urinary bladder. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer,
Adrenal Anatomy of the adrenal gland. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer, ©American.
Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas Regional lymph nodes for skin sites of the head and neck. Compton, C.C., Byrd, D.R., et.
Melanoma of the Skin Regional lymph nodes for skin sites of the head and neck. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd.
Intrahepatic Bile Ducts Liver diagram differentiating intrahepatic bile ducts from extrahepatic bile ducts and showing a mass-forming type of intrahepatic.
New Data Items MP/H Task Force Multiple Primary Rules Histology Coding Rules 2007.
Exocrine and Endocrine Pancreas Anatomic subsites of the pancreas. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New.
Bone The anatomic subsites of the bone. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer, ©American.
TNM Staging: Prostate TONYA BRANDENBURG, MHA, CTR KENTUCKY CANCER REGISTRY.
TNM Staging: Breast TONYA BRANDENBURG, MHA, CTR KENTUCKY CANCER REGISTRY.
Ovary and Primary Peritoneal Carcinoma Anatomic sites of the ovary and peritoneum. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas,
TNM Staging: Colon and Rectum
Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry
Breast Anatomic sites and subsites of the breast. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer,
ajcc TNM Staging: chapter 1, and Summary stage
Collaborative Staging for Colon Site Specific Factors Tonya Brandenburg, MHA, CTR QA Manager Abstracting and Coding Kentucky Cancer Registry.
Kidney Anatomical site of the kidney. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer, ©American.
CSv2 for the Hematopoietic Neoplasms 1. 2 This includes five schemas …. Hematopoietic, Reticuloendothelial, Immunopro-liferative and Myeloproliferative.
PATHOLOGY OF NECK DISSECTION. VIEW FROM DEEP ASPECT OF NECK DISSECTION.
NPCR Data Completeness and Quality Audits Review of: Collaborative Stage and Surgery Data Mary Lewis, CTR NPCR Program Consultant.
The Malignant Polyp Handout Version Hans Elzinga, MD Program Director- Advanced Procedures in Family Medicine Fellowship Salud Family Health Center-Longmont,
Cancer: Staging and Grading What is meant by the term “biopsy”? How do tumors behave differently from one another ? Examples of the stages of cancer and.
Fallopian Tube Anatomic site of the fallopian tube. Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer,
Anus Anatomic subsites of the anus. The epithelium in the peri-anal region and the vulvar zone is at risk for squamous carcinomas, along with HPV and other.
Tumor markers 1111.
THE IMPORTANCE OF STAGING AND PROGNOSTIC FACTORS IN CANCER CARE
Ultrasound breast core needle biopsy
Creating the perfect text…
Tumor Grade.
What’s New for 8th Edition
Tonya Brandenburg, mha, ctr Nicole Catlett, Ctr
SEER EOD and Summary Stage
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2 1.
Changes in TNM 8 To be used from
NSCLC: Staging and TNM classification
Presentation transcript:

Collaborative Staging for Colon Site Specific Factors -You’ve already heard about the core CS fields that are coded for every site - what are SSF’s? Tonya Brandenburg, MHA, CTR QA Manager Abstracting and Coding Kentucky Cancer Registry

Site specific factors Collect additional information in order to generate AJCC stage Record important prognostic indicators A site may have anywhere from zero to twenty-five SSF’s Part One, Section Two of the Collaborative Staging Manual contains coding instructions for the SSF’s Additional info for staging- i.e., thickness of melanoma, extracapsular ext in LN’s for H&N Lab values and tumor markers- CEA for colon, AFP for testis, etc. Factors that predict survival or response to therapy- i.e., “B” sxs in lymphoma or HER-2 positivity in breast ca Associated diseases or conditions: HPV infection in H/N, HIV/AIDS for Kaposi -With the advent of CSv2, some SSF’s that were collected CSv1 were made obsolete, while several others were added - Part one, section 2 has a wealth of information, particularly regarding lab tests and values, how to round, converting units, etc.

Site specific factors -Can be download to your desktop from the CS web site -Hyperlinked, so you can jump directly to the topic you want

Site specific factors -Tells you which schemas it appears in -Defines what CEA is and how it’s tested -Provides reference range

Site specific factors SSF25 functions as a schema discriminator for some sites For those sites, SSF25 is coded when you create the case or if the case is key changed to a site that requires a discriminator -For a few sites (for example, esophagus/GE junction), SSF25 distinguishes between two different staging schemas (in that case, stomach vs esophagus), also primary peritoneum, bile duct.

Colon Site Specific Factors Colon has ten site specific factors Seven of these are required by SEER SSF’s 5, 7, and 10 are not required Default code for SSF’s that are not collected = 988 -Some CS codes consistent across sites (i.e. CEA value is recorded in SSF1 for colon, appendix, and rectum) -Default code for SSF’s that are not required is 988, for all sites-Cpdms.net will autofill this for you

SSF1: CEA Interpretation 010 Positive/elevated 020 Negative/normal; within normal limits 030 Borderline; undetermined if positive or negative 997 Test ordered, results not in chart OR 998 Test not done (test not ordered and not performed) 999 Unknown or no information; not documented in patient record -CEA stands for “carcinoembryonic antigen.” It is a protein molecule normally found in many kind of cells, but elevated rates are associated with certain tumors, particularly in GI malignancies. An elevated rate isn’t diagnostic of cancer, because other conditions (like smoking) can cause this. The higher the CEA, the more likely it is the cancer has metastasized. -Part one, section two of the CS Manual instructs registrars to code the interpretation of the CEA lab value as stated *by the clinician*.

SSF2: Clinical Assess-ment of Regional Lymph Nodes -This field is needed in order to derive AJCC stage -It can be important in rectal cancer and low sigmoid cancers, where pre-operative chemo or XRT may be given prior to surgery, thus making clinical staging important

SSF2: Clinical Assessment of LN’s Note 1:  Clinically evident regional lymph nodes are based on information from the diagnostic workup.  This might include:  physical examination, imaging, diagnostic lymph node biopsy and exploratory surgery (without a resection).  Note 2:  In the rare instance that the number of clinically positive nodes is stated but a clinical N category is not stated, use the code that reflects the most specific statement about the number of nodes. Note 3:  If there is no diagnostic work-up to assess regional lymph nodes, use code 999.  Do not apply the inaccessible nodes rule that presumes unmentioned nodes to be negative. -Very important to read notes!!! -They contain essential info; failing to read them could result in miscoding! -The exception to Note 3 would be in situ tumors.

SSF2: Clinical Assessment of LN’s 000 Nodes not clinically evident; imaging of regional nodes performed and nodes not mentioned 010 Metastasis in 1 regional node, determined clinically OR stated as clinical N1a 020 Metastases in 2-3 regional nodes, determined clinically OR stated as clinical N1b 030 OBSOLETE -The obsolete code is left in because of cases that were coded in CS version one (2004-2010)

SSF2: Clinical Assessment of LN’s 100 Metastases in 1-3 regional nodes, determined clinically or stated as clinical N1 [NOS] 110 Metastases in 4-6 regional nodes, determined clinically or stated as clinical N2a 120 Metastases in 7 or more regional nodes, determined clinically or stated as clinical N2b 200 Metastases in 4 or more regional nodes, determined clinically Stated as clinical N2 [NOS] 400 Clinically positive regional node(s), NOS -Always use the more specific code over the general

SSF2: Clinical Assessment of LN’s 888 OBSOLETE 988 Not applicable: Information not collected for this case (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.) 999 Regional lymph node(s) involved pathologically, clinical assessment not stated or unknown if regional lymph nodes clinically evident; not documented in patient record -Do NOT use code 988 for SSF’s that are required Use code 999 when there is no diagnostic work-up to assess regional lymph nodes there is no imaging or ultrasound reported it is unknown whether imaging or ultrasound was done a scan or ultrasound states adenopathy is present without making a definite statement that the nodes are clinically positive (such as fixed, matted, or metastatic terminology). The terms adenopathy, enlargement, suspicious, and so forth, by themselves are not sufficient to code as involvement. For example, statements of “adenopathy” or “suspicious lymph nodes” should be coded as 999, but a statement of “lymph nodes suspicious for malignancy” should be coded as 400.

SSF3: CEA Lab Value Note 1:  CEA is a tumor marker that has value in the management of certain malignancies. Note 2:  The same laboratory test should be used to record information in CS Site-Specific Factors 1 and 3. Note 3:  Record to the nearest tenth in nanograms/milliliter (ng/ml) the highest CEA lab value documented in the medical record prior to treatment.  For example, code a pretreatment CEA of 7 ng/ml as 070. -SSF1 recorded the *interpretation* of the value- SSF3 records the actual result of testing -Note 2- important to use same test

SSF3: CEA Lab Value Note 4:  Code 000 is reserved for exactly 0.0 ng/ml (no measurable amount of CEA).  Do not round tiny values down to 0.0 ng/ml; any measured value less than or equal to 0.1 ng/ml should be coded 001.  For code 001, also round 0.11-0.14 ng/ml down to 0.1 ng/ml.  For codes 002-980, round values to the nearest tenth of a ng/ml. Note 5:  For an uncertain value, record the stated closest value.  For example, code a value stated as "less than 0.5 ng/ml" as 005. -You may need to round!

SSF 3: CEA Lab Value 000 0.0 nanograms/milliliter (ng/ml) exactly 001 0.1 or less ng/ml; stated as less than 0.1 ng/ml with no exact value 002-979 0.2-97.9 ng/ml; (Exact value to nearest tenth in ng/ml) 980 98.0 or greater ng/ml

SSF 3: CEA Lab Value 988 Not applicable: Information not collected for this case; (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.) 997 Test ordered, results not in chart 998 Test not done (test not ordered and not performed) 999 Unknown or no information; not documented in patient record -These codes explain why no CEA value was available -998 is only used in the rare instance when it is stated in the medical record that the test was NOT done; if you don’t see whether it was done, use 999

SSF4: Tumor Deposits Note 1:  Tumor deposits (TD) are defined as one or more satellite peritumoral nodules in the pericolorectal adipose tissue of a primary carcinoma without histologic evidence of residual lymph node in the nodule.  Such TD may represent discontinuous spread, venous invasion with extravascular spread, or a totally replaced lymph node. -Tumor nodules in the fat outside the colon or rectum that have no LN structure

SSF4: Tumor Deposits Note 2:  Record the number of TD whether or not there are positive lymph nodes. Note 3:  Assign code 000 if surgical resection of the primary site is performed, the pathology report is available for review, and tumor deposits are not mentioned. -Do not code actual LN’s in the field -This info should be on the CAP protocol for the resection of the primary site

SSF4: Tumor Deposits 000 None 001-080 1-80 Tumor deposits (TD)(Exact # of TD) 081 81 or more TD 888 OBSOLETE

SSF4: Tumor Deposits 988 Not applicable: Information not collected for this case; (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.) 990 TD identified, number unknown 998 No surgical resection of primary site 999 Unknown or no information; Insufficient information; indeterminate if TD present; Not documented in patient record

SSF5 is not required! Nap with a friend. Code 988 is entered by default

SSF6: Circumferential Resection Margin The CRM may also be referred to as the circumferential radial margin or mesenteric margin The CRM is a significant prognostic indicator for recurrence, so it’s important to record it accurately Note 4:  Record to the nearest tenth in millimeters (mm) the distance between the leading edge of the tumor and the nearest edge of surgically dissected margin as recorded in the pathology report.  For example, if the CRM is 2 mm, code 020.  If the margin is involved (positive), use code 000.  If the margin is described as less than 1 mm with no more specific measurement, use code 000; margins of 0-1 mm are recorded by the pathologist as involved. -CRM is the most important factor in predicting local recurrence -Should also be on CAP protocol

Parts of the colon wall (and rectum) are covered by the visceral peritoneum (as seen on the left above); some parts are not (as seen on the right). When the surgeon dissects the non-serosalized parts, the CRM is the margin between the colon itself, and the mesentery. SSF6: CRM Circumferential resection margin. T4a (left side) has perforated the visceral peritoneum. In contrast, T3; R2 (right side) shows macroscopic involvement of the circumferential resection margin of a non- peritonealized surface of the colorectum by tumor with gross disease remaining after surgical excision Compton, C.C., Byrd, D.R., et al., Editors. AJCC CancerStaging Atlas, 2nd Edition. New York: Springer, 2012. ©American Joint Committee on Cancer

SSF6: CRM 000 Margin IS involved with tumor; Circumferential resection margin (CRM) positive; Described as "less than 1 millimeter (mm)“ 001-980 0.1- 98.0 millimeter (mm); (Exact size to nearest tenth of millimeter) 981 98.1 mm or greater -

SSF6: CRM 988 Not applicable: Information not collected for this case; (May include cases converted from code 888 used in CSv1 for "Not applicable" or when the item was not collected. If this item is required to derive T, N, M, or any stage, use of code 988 may result in an error.) 990 No residual tumor identified on specimen 991 Margins clear, distance from tumor not stated -990, for example, polypectomy during colonoscopy, no residual dz on colon resection -991 states CRM is negative, but no measurement given

SSF6: CRM 992 Described as "less than 2 mm," or "greater than 1 mm," or "between 1 mm and 2 mm" 993 Described as "less than 3 mm," or "greater than 2 mm," or "between 2 mm and 3 mm" 994 Described as "less than 4 mm," or "greater than 3 mm," or "between 3 mm and 4 mm" 995 Described as "less than 5 mm," or "greater than 4 mm," or "between 4 mm and 5 mm" 996 Described as "greater than 5 mm" -More ‘described as’ codes…

SSF6: CRM 998 No resection of primary site 999 Unknown or no information; CRM not mentioned; Not documented in patient record

SSF6: CRM Read through all codes! Note that there are specific codes for situations in which there is no residual tumor in the resected specimen (990) and when no resection of the primary site is done (998)

SSF 7 is not required Take a break with some friends Code 988

SSF8: Perineural Invasion Note: Code the presence or absence of perineural invasion as documented in the pathology report. Assign code 000 if histologic examination of primary site was performed, the pathology report is available for review, and perineural invasion is not mentioned. -This SSF documents whether tumor cells has spread along nerve pathways; *not* invasion of the actual nerve itself -The cancer cells are spreading along the path of least resistance -Tumors with perineural invasion have a poorer prognosis than those without it -If it’s not mentioned in the path report, assume it’s not present

SSF8: Perineural Invasion 000 None; no perineural invasion present 010 Perineural invasion present 988 Not applicable: Information not collected for this case; (If this information is required by your standard setter, use of code 988 may result in an edit error.) 998 No histologic examination of primary site 999 Unknown; Not documented in patient record

SSF9: KRAS KRAS is a gene which belongs to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous. Studies suggest that KRAS gene mutations are often present in colorectal cancer. -normal KRAS is also referred to as “wild type,” meaning unmutated -tumors with a mutated KRAS are unlikely to respond to certain expensive and toxic drugs (i.e., cetuximab [Erbitux])

SSF9: KRAS 010 Abnormal (mutated); Positive for mutations 020 Normal (wild type); Negative for mutations 988 Not applicable: Information not collected for this case (If this information is required by your standard setter, use of code 988 may result in an edit error.)

SSF9: KRAS 997 Test ordered, results not in chart 998 Test not done (test was not ordered and was not performed) 999 Unknown; Not documented in patient record ASCO recommends that Stage IV colorectal patients be tested for KRAS if anti-EGFR therapy is being considered. Code 999 will usually be coded for colon cancer patients with Stage 1 or Stage 2 cancer.

Questions?